- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
COVID-19 and Cardiovascular Disease: Clinical Guidance for Primary Care
The case fatality rate for patients with COVID-19 and CVD is higher than for cancer, chronic respiratory disease, and diabetes. Here is current guidance from the ACC.
The reported case fatality rate for patients with COVID-19 infection who have underlying cardiovascular disease (CVD) is approximately 10% -- higher than for cancer, chronic respiratory disease, and diabetes. The American College of Cardiology recently published a clinical bulletin titled "COVID-19 Clinical Guidance for the CV Care Team." The majority of the information is also highly relevant for primary care physicians who routinely see patients with a full range of CVD and related morbidity.Click through the short slide show below for a summary of the bulletin curated for primary care.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
